Abiraterone acetate is a medication used to treat prostate cancer. It is sold under the brand name Zytiga. More specifically it is used together with a corticosteroid for castration-resistant prostate cancer or mCRPC and metastatic high-risk metastatic castration-sensitive prostate cancer or mCSPC. It should be used in cases following removal of the testicles or along with a gonadotropin-releasing hormone (GnRH) analog. It is an oral medication.
Common side effects are such as tiredness, vomiting, headache, joint pain, high blood pressure, swelling, low blood potassium, high blood sugar, hot flashes, diarrhea, and cough. Other severe side effects may include adrenocortical insufficiency and liver failure. Birth control is recommended in males whose partners can become pregnant. Supplied as abiraterone acetate it is converted in the body to abiraterone.
Abiraterone acetate suppresses the production of androgens, specifically, it inhibits CYP17A1 and decreases the production of testosterone. Thus it prevents the effects of these hormones in prostate cancer.
Abiraterone acetate was demonstrated in 1995 and gained approval for medical use in the United States and Europe in 2011. The World Health Organization listed in Essential Medicines, as the safest and most effective medicines needed in a health system. This medication is marketed widely throughout the world.
Abiraterone acetate is used in combination with prednisone a corticosteroid, as a treatment for mCRPC (previously known as hormone-resistant or hormone-refractory prostate cancer). This is a kind of prostate cancer that does not respond to first-line androgen deprivation therapy or treatment with androgen receptor antagonists. Abiraterone acetate has received approval from:
Food and Drug Administration (FDA) (28 April 2011),
European Medicines Agency (EMA) (23 September 2011),
Medicines and Healthcare products Regulatory Agency (MHRA) (5 September 2011)
And Therapeutic Goods Administration (TGA) (1 March 2012) for this indication.
it is covered by the Pharmaceutical Benefits Scheme In Australia, specifically when it is used to treat castration-resistant prostate cancer in combination with prednisone/prednisolone. The patient who is not currently receiving chemotherapy has been found either resistant or intolerant of docetaxel. The patient has a WHO performance status of <2. Besides his disease has not become progressive since treatment with PBS-subsidised abiraterone acetate has commenced.
Contraindications include hypersensitivity to abiraterone acetate. Although documents state that it should not be taken by women. Specifically, who are pregnant or may become pregnant. There is no medical reason for any woman to take it. Pregnant women should not even touch the pills unless they are wearing gloves. Other cautions include:
severe baseline hepatic impairment,
mineralocorticoid excess, cardiovascular disease like
heart failure and hypertension,
How Does Abiraterone acetate Work?
Abiraterone works by stopping the body’s production of a hormone called testosterone. It is usually done in a different way to other types of hormone therapy. Prostate cancer cells can't grow without testosterone, in most men. Even if they have spread to other parts of the body, they can't grow without it.
The Wholesale Price of Abiraterone acetate
The wholesale price of this pharmaceutical substance is around $50-65 USD per medicine. The price may vary and depends on the pharmacy you visit.
Sourcing Abiraterone Manufacturers and Abiraterone acetate Suppliers
Those who are looking for an easy and convenient way to source and order abiraterone may search online using Pipelinepharma's marketplace. Through our strict evaluation and quality control process, you are assured to find verified abiraterone manufacturers and suppliers.